10-Q: Dermata Therapeutics Reports Q2 Loss, Positive Trial Data

Dermata Therapeutics, a clinical-stage dermatology company, reported a reduced net loss in Q2 2025 and positive Phase 3 trial results for its lead acne candidate XYNGARI, but faces significant going concern doubts and Nasdaq delisting risk.

Summary

• Dermata Therapeutics reported a net loss of $1.7 million for the three months ended June 30, 2025, an improvement from a $2.8 million net loss in the same period of 2024.
• For the six months ended June 30, 2025, the net loss was $4.0 million, down from $6.0 million in the prior year period.
• Research and development expenses decreased by $1.4 million to $0.6 million for Q2 2025, and by $1.7 million to $1.9 million for the six months ended June 30, 2025, primarily due to the completion of the XYNGARI STAR-1 acne study.
• General and administrative expenses increased by $0.3 million to $1.2 million for Q2 2025, driven by increased public company compliance and personnel costs.
• The company's cash and cash equivalents stood at $6.5 million as of June 30, 2025, with an accumulated deficit of $69.7 million.
• Cash used in operations for the six months ended June 30, 2025, was $4.6 million.
• The company expects its current cash to fund operations into the second quarter of 2026.
• Positive topline results were announced in March 2025 for the XYNGARI Phase 3 STAR-1 clinical trial for moderate-to-severe acne, meeting all co-primary endpoints with statistically significant differences compared to placebo.
• The company completed capital raises totaling approximately $7.9 million in net proceeds during the six months ended June 30, 2025, through a January 2025 PIPE and a March 2025 Warrant Inducement.
• Dermata Therapeutics received a Nasdaq non-compliance letter on May 14, 2025, for failing to meet the $1.00 minimum bid price requirement and is subject to delisting due to a prior reverse stock split; an exception was granted until August 14, 2025.
• A 1-for-10 reverse stock split was approved by stockholders on July 15, 2025, and effected on August 1, 2025, to address Nasdaq compliance.

Sentiment

Score: 4

Explanation: While positive Phase 3 clinical trial results for XYNGARI are a significant scientific achievement for a clinical-stage biotech, the severe financial distress, including substantial doubt about going concern and immediate Nasdaq delisting risk, creates an extremely high-risk investment profile. The capital raises are essential but highlight the continuous need for funding without a clear path to profitability, making the overall sentiment cautious to negative despite the clinical progress.

Positives

• Reported positive topline results for the XYNGARI Phase 3 STAR-1 clinical trial in moderate-to-severe acne, meeting all co-primary endpoints with high statistical significance.
• XYNGARI demonstrated rapid and sustained therapeutic effects in reducing inflammatory and noninflammatory lesion counts, and improving investigator's global assessment (IGA) of acne.
• Net loss significantly decreased to $1.7 million in Q2 2025 from $2.8 million in Q2 2024, and to $4.0 million for the six months ended June 30, 2025, from $6.0 million in the prior year period.
• Successfully raised approximately $7.9 million in net proceeds from equity financings (January 2025 PIPE and March 2025 Warrant Inducement) during the first half of 2025, bolstering cash reserves.
• Cash and cash equivalents increased to $6.5 million as of June 30, 2025, from $3.2 million at December 31, 2024.
• Entered into a clinical trial collaboration agreement with Revance Therapeutics, Inc. to evaluate XYNGARI with Daxxify for primary axillary hyperhidrosis, indicating potential for pipeline expansion and partnerships.

Negatives

• The company has an accumulated deficit of $69.7 million as of June 30, 2025, indicating a history of significant losses.
• Management has identified substantial doubt about the company's ability to continue as a going concern for the next year, necessitating additional capital raises.
• Received a Nasdaq non-compliance letter for failing to meet the minimum bid price requirement and is subject to delisting, with an exception granted only until August 14, 2025.
• The company has not generated any revenue since its inception and expects to incur significant operating losses for the foreseeable future.
• Reliance on a single Russian entity for the exclusive supply of Spongilla raw material, which could be negatively impacted by geopolitical events and sanctions.
• Increased general and administrative expenses in Q2 2025 compared to Q2 2024, partly due to public company compliance costs.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to historical and expected operating losses and net operating cash flow deficits.
• Inability to raise additional capital on favorable terms, or at all, which would negatively impact financial condition and business strategy.
• Dependence on product candidates still in clinical development, with no approved products or revenue generation to date.
• Risk of delisting from The Nasdaq Capital Market due to non-compliance with the minimum bid price requirement.
• Potential adverse impact on business, results of operations, and financial condition if the exclusive supply of Spongilla raw material from a Russian entity is disrupted by sanctions or export controls.
• Uncertainty regarding the success and timing of future clinical trials, including the required second Phase 3 trial (STAR-2) for XYNGARI in acne.
• Reliance on third-party contract research organizations (CROs) to conduct clinical trials and third-party manufacturers for product candidates.
• Inability to maintain or protect the validity of intellectual property, or to internally develop new inventions and intellectual property.
• Exposure to fluctuations in operating results due to the progress and timing of expenditures related to product candidate development.

Future Outlook

The company anticipates continued net losses for the foreseeable future and expects expenses to increase significantly with future activities, including the development of XYNGARI for acne (requiring a second Phase 3 trial), preparation for regulatory approval, identification of a botulinum toxin partner for DMT410, and potential commercialization efforts. Additional financing will be required to support operations beyond Q2 2026, and the company plans to seek further equity or debt financings, or collaboration agreements.

Management Comments

• Management believes the combination of Spongilla's mechanical and chemical components adds to the versatility of their technology platform's effectiveness as a singular product for a wide variety of medical skin diseases.
• Management believes the mechanical properties of their Spongilla technology allow for the intradermal delivery of large molecules, like botulinum toxins, through topical application without the need for needles.
• Management expects that as research and development expenses continue to grow, the company will need to raise additional capital to sustain operations and research and development.

Industry Context

Dermata Therapeutics operates in the highly competitive and capital-intensive medical dermatology and aesthetic markets. The company's focus on a proprietary Spongilla technology for topical treatments aims to address limitations of current therapies, such as efficacy, application regimens, and side effects. The positive Phase 3 results for XYNGARI in acne position it as a potential new entrant in a large market (estimated 30 million U.S. patients). The collaboration with Revance Therapeutics for DMT410 in hyperhidrosis (a market where 40% of patients are treated with botulinum toxin injections) indicates a strategy to leverage its delivery platform for existing high-value compounds, potentially disrupting traditional injection-based treatments.

Comparison to Industry Standards

• The company's XYNGARI Phase 3 STAR-1 trial results for acne, demonstrating statistically significant improvements across primary endpoints (IGA success, inflammatory and noninflammatory lesion reduction), are competitive with efficacy profiles seen in other topical acne treatments, though direct comparisons to specific competitor trial results are not provided in the filing.
• The company's cash runway into Q2 2026, coupled with significant accumulated deficit and ongoing losses, is typical for clinical-stage biotechnology companies that have not yet commercialized products, but it highlights a continuous need for capital, which is a common challenge in the industry.
• The repeated use of warrant inducements and PIPE financings, including insider participation, is a common capital-raising strategy for small-cap biotechs, but also reflects the difficulty in securing non-dilutive funding without commercial products.

Corporate Governance

Related Party Transactions

• Certain company insiders, including the CEO, CFO, and certain board members, participated in the January 2025 PIPE financing, purchasing an aggregate of 122,047 shares of Common Stock and 122,047 PIPE Warrants for approximately $1.55 million. The purchase price was the same as paid by other investors.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing and future equity capital raises. The Nasdaq delisting threat poses a direct risk to liquidity and market visibility. The 1-for-10 reverse stock split aims to maintain listing but reduces the number of shares held.
• **Employees**: Stock-based compensation is a component of their remuneration, and the equity incentive plan amendment provides for future awards. However, the company's going concern uncertainty could impact job security and morale.
• **Customers (future)**: Potential for new treatment options for acne and hyperhidrosis if product candidates are successfully developed and commercialized.
• **Suppliers**: The exclusive supply agreement with a Russian entity for Spongilla raw material introduces geopolitical risk, potentially impacting the company's ability to manufacture its product candidates.
• **Creditors**: The substantial accumulated deficit and going concern doubt indicate elevated credit risk, potentially making future debt financing more challenging or expensive.

Next Steps

• Evaluate the full data set from the XYNGARI Phase 3 STAR-1 trial.
• Determine next steps for the XYNGARI Phase 3 STAR-2 clinical trial, which is required by the FDA and would be followed by a 12-month extension study.
• Initiate a Phase 2a clinical trial for XYNGARI with Daxxify for primary axillary hyperhidrosis in collaboration with Revance Therapeutics, Inc.
• Identify a botulinum toxin partner for DMT410 for the treatment of medical and aesthetic skin conditions and diseases.
• Continue development of DMT410, including Phase 1 and Phase 2 clinical trials.
• Prepare for regulatory approval of XYNGARI for moderate-to-severe acne.
• Prepare for commercialization of XYNGARI, if approved, including hiring sales and marketing personnel.
• Manufacture product candidates for additional Phase 2 and Phase 3 trials and commercial sale.
• Raise additional capital through equity or debt financings, or through product development, technology licensing, or collaboration transactions to sustain operations and research and development.
• Regain and maintain compliance with Nasdaq listing requirements, specifically the minimum bid price requirement, by August 14, 2025.

Key Dates

Recommendation

While Dermata Therapeutics has achieved a significant milestone with positive Phase 3 clinical trial results for XYNGARI, which is a strong positive for a clinical-stage biotech, the company faces critical financial challenges. The explicit 'substantial doubt about going concern' and the immediate threat of Nasdaq delisting due to minimum bid price non-compliance create immense uncertainty and risk. Although recent capital raises have provided a temporary cash infusion, the company will require significant additional funding to complete further trials and pursue commercialization. For a seasoned investor, the positive clinical data suggests long-term potential, but the severe financial instability and regulatory hurdles make it a highly speculative investment. A 'hold' recommendation implies acknowledging the pipeline's promise while recognizing the extreme financial and operational risks that could severely impact the company's ability to capitalize on its clinical success. It is not a 'buy' due to the high risk of capital loss, nor a 'sell' given the potential upside if the financial issues are resolved and the pipeline progresses.

Keywords

Dermatology, Biotechnology, Clinical-stage, Acne, XYNGARI, DMT410, Spongilla, Phase 3 trial, Nasdaq compliance, Going concern, Capital raise, SEC filing, 10-Q, Clinical trials, Skin conditions, Hyperhidrosis, Psoriasis